Comparative Pharmacology
Head-to-head clinical analysis: FENTORA versus PROPOXYPHENE HYDROCHLORIDE 65.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTORA versus PROPOXYPHENE HYDROCHLORIDE 65.
FENTORA vs PROPOXYPHENE HYDROCHLORIDE 65
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent mu-opioid receptor agonist, binding to and activating opioid receptors in the brain and spinal cord, leading to analgesia and sedation.
Propoxyphene is a centrally acting opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting pain signal transmission and altering pain perception. It also has local anesthetic effects.
For opioid-tolerant adults: 100 mcg (one tablet) placed in buccal cavity; titrate upward in increments of 100 mcg per breakthrough pain episode, with minimum 2-hour interval between doses; maximum 4 doses per day.
65 mg orally every 4 hours as needed for pain; maximum 390 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours in adults, but can range from 2 to 6 hours depending on hepatic clearance. In elderly or hepatically impaired patients, half-life may be prolonged. The rapid initial decline is due to redistribution, and the terminal phase reflects slow elimination from deep compartments.
6-12 hours (mean ~8 hours); prolonged in hepatic impairment and elderly; accumulation possible with repeated dosing.
Primarily renal: Approximately 75% of the dose is excreted in urine as metabolites (mostly norfentanyl, despropionylfentanyl, and hydroxyfentanyl), with less than 7% as unchanged fentanyl. Fecal elimination accounts for about 9%.
Renal excretion of unchanged drug (approximately 20-30%) and metabolites; approximately 40-60% as conjugated metabolites; minor biliary/fecal elimination.
Category C
Category C
Opioid Analgesic
Opioid Analgesic